Natural products in drug discovery

Drug Discovery Today

Volumn 13, Issue 19-20, 2008, Pages 894-901

  Harvey, Alan L ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CASPOFUNGIN; CRYPTOPHYCIN DERIVATIVE; CURACIN A; DAPTOMYCIN; DOLASTATIN 10; ELLIPTINIUM; EVEROLIMUS; GALANTAMINE; HUPERZINE A; IXABEPILONE; MICAFUNGIN; NATURAL PRODUCT; PLATENSIMYCIN; RETAPAMULIN; SALINOSPORAMIDE A; SORAFENIB; TELITHROMYCIN; TIGECYCLINE; TRABECTEDIN; VANCOMYCIN;

DRUG ACTIVITY; DRUG INDICATION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; REVIEW; TRADITIONAL MEDICINE; TREATMENT INDICATION;

ANIMALS; BIOLOGICAL PRODUCTS; COMPUTER SIMULATION; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; PHARMACOLOGY;

EID: 52049109838     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.07.004     Document Type: Review

References (60)

1. Sneader W. Drug Prototypes and Their Exploitation (1996), Wiley, UK
2. Newman D.J., and Cragg G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 70 (2007) 461-477
3. Butler M.S. Natural products to drugs: natural product-derived compounds in clinical trials. Nat. Prod. Rep. 25 (2008) 475-516
4. Chin Y.-W., et al. Drug discovery from natural sources. AAPS J. 8 (2006) E239-E253
5. Lam K.S. New aspects of natural products in drug discovery. Trends Microbiol. 15 (2007) 279-289
6. Ganesan A. The impact of natural products upon modern drug discovery. Curr. Opin. Chem. Biol. 12 (2008) 306-317
7. Singh S.B., and Barrett J.F. Empirical antibacterial drug discovery- foundation in natural products. Biochem. Pharmacol. 71 (2006) 1006-1015
8. Baker D.D., et al. The value of natural products to future pharmaceutical discovery. Nat. Prod. Rep. 24 (2007) 1225-1244
9. McChesney J.D. Plant natural products: back to the future or into extinction?. Phytochemistry 68 (2007) 2015-2022
10. Rishton G.M. Natural products as a robust source of new drugs and drug leads: past successes and present day issues. Am. J. Cardiol. 101 Suppl. (2008) 43D-49D
11. Harvey A.L. Natural Product Pharmaceuticals: A Diverse Approach to Drug Discovery, Scrip Reports (2001), PJB Publications
12. Charlish P. Traditional remedies: latter day medicines. Scrip World Pharmaceutical News 3351 (2008) 31-34
13. Feher M., and Schmidt J.M. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inf. Comput. Sci. 43 (2003) 218-227
14. Grabowski K., and Schneider G. Properties and architecture of drugs and natural products revisited. Curr. Chem. Biol. 1 (2007) 115-127
15. Galm U., and Shen B. Natural product drug discovery: the times have never been better. Chem. Biol. 14 (2007) 1098-1104
16. Harvey A.L. Strategies for discovering drugs from previously unexplored natural products. Drug Dis. Today 5 (2000) 294-300
17. Lam K.S. Discovery of novel metabolites from marine actinomycetes. Curr. Opin. Microbiol. 9 (2006) 245-251
18. Fenical W., and Jensen P.R. Developing a new resource for drug discovery: marine actinomycete bacteria. Nat. Chem. Biol. 2 (2006) 666-673
19. Bull A.T., and Stach J.E. Marine actinobacteria: new opportunities for natural product search and discovery. Trends Microbiol. 15 (2007) 491-499
20. Tan L.T. Bioactive natural products from marine cyanobacteria for drug discovery. Phytochemistry 68 (2007) 954-979
21. Harvey A.L. Natural products as a screening resource. Curr. Opin. Chem. Biol. 11 (2007) 480-484
22. Cox R.J. Polyketides, proteins and genes in fungi: programmed nano-machines begin to reveal their secrets. Org. Biomol. Chem. 5 (2007) 2010-2026
23. Zhang M.Q., and Wilkinson B. Drug discovery beyond the 'rule-of-five'. Curr. Opin. Biotechnol. 18 (2007) 478-488
24. Floss H.G. Combinatorial biosynthesis- potential and problems. J. Biotechnol. 124 (2006) 242-257
25. Chang M.C.Y., and Keasling J.D. Production of isoprenoid pharmaceuticals by engineered microbes. Nat. Chem. Biol. 2 (2006) 674-681
26. Chemler J.A., et al. Combinatorial mutasynthesis of flavonoid analogues from acrylic acids in microorganisms. Org. Lett. 9 (2007) 1855-1858
27. McAlpine J.B., et al. Microbial genomics as a guide to drug discovery and structural elucidation: ECO-02301, a novel antifungal agent, as an example. J. Nat. Prod. 68 (2005) 493-496
28. Kennedy J., et al. Metagenomic approaches to exploit the biotechnological potential of the microbial consortia of marine sponges. Appl. Microbiol. Biotechnol. 75 (2007) 11-20
29. Lefevre F., et al. Drugs from hidden bugs: their discovery via untapped resources. Res. Microbiol. 159 (2008) 153-161
30. Barrios-Llerena M.E., et al. Genetic analysis of polyketide synthase and peptide synthetase genes in cyanobacteria as a mining tool for secondary metabolites. J. Ind. Microbiol. Biotechnol. 34 (2007) 443-456
31. Gillespie D.E., et al. Isolation of antibiotics turbomycin a and B from a metagenomic library of soil microbial DNA. Appl. Environ. Microbiol. 68 (2002) 4301-4306
32. Kennedy J. Mutasynthesis, chemobiosynthesis, and back to semi-synthesis: combining synthetic chemistry and biosynthetic engineering for diversifying natural products. Nat. Prod. Rep. 25 (2008) 25-34
33. Kopp F., and Marahiel M.A. Where chemistry meets biology: the chemoenzymatic synthesis of nonribosomal peptides and polyketides. Curr. Opin. Biotechnol. 18 (2007) 513-520
34. Lamb D.C., et al. Cytochromes P450 and drug discovery. Curr. Opin. Biotechnol. 18 (2007) 504-512
35. Wilson R.M., and Danishefsky S.J. Small molecule natural products in the discovery of therapeutic agents: the synthesis connection. J. Org. Chem. 71 (2006) 8329-8351
36. Newman D.J. Natural products as leads to potential drugs: an old process or the new hope for drug discovery?. J. Med. Chem. 51 (2008) 2589-2599
37. Sunazuka T., et al. Efficient total synthesis of novel bioactive microbial metabolites. Acc. Chem. Res. 41 (2008) 302-314
38. Boldi A.M. Libraries from natural product-like scaffolds. Curr. Opin. Chem. Biol. 8 (2004) 281-286
39. Yao N., et al. Synthesis of flavonoid analogues as scaffolds for natural product-based combinatorial libraries. J. Comb. Chem. 9 (2007) 668-676
40. Ertl P., et al. Natural product-likeness score and its application for prioritization of compound libraries. J. Chem. Inf. Model. 48 (2008) 68-74
41. Wu S., et al. Multi-channel counter-current chromatography for high-throughput fractionation of natural products for drug discovery. J. Chromatogr. A 1180 (2007) 99-107
42. Quinn R.J., et al. Developing a drug-like natural product library. J. Nat. Prod. 71 (2008) 464-468
43. Littleton J., et al. Novel approaches to plant drug discovery based on high throughput pharmacological screening and genetic manipulation. Life Sci. 78 (2005) 467-475
44. Singh S.B., et al. Highly sensitive target-based whole-cell antibacterial discovery strategy by antisense RNA silencing. Curr. Opin. Drug Discov. Dev. 10 (2007) 160-166
45. Wang J., et al. Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 7612-7616
46. Parsons A.B., et al. Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 126 (2006) 611-625
47. Cheng Y., et al. A causal relationship discovery-based approach to identifying active components of herbal medicine. Comput. Biol. Chem. 30 (2006) 148-154
48. Wang Y., et al. Discovering active compounds from mixtures of natural products by data mining approach. Med. Biol. Eng. Comput. 46 (2008) 605-611
49. Ehrman T.M., et al. Virtual screening of Chinese herbs with Random Forest. J. Chem. Inf. Model. 47 (2007) 264-278
50. Ehrman T.M., et al. Phytochemical informatics of traditional Chinese medicine and therapeutic relevance. J. Chem. Inf. Model. 47 (2007) 2316-2334
51. Chen X., et al. Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validation. Brit. J. Pharmacol. 149 (2006) 1092-1103
52. Xu Q., et al. NCL-3D: a 3D natural compound library for structure-based drug discovery. 1st International Conference Bioinform. Biomed. Eng. ICBBE (2007) 367-369
53. Do Q.Y., et al. Reverse pharmacognosy: identifying biological properties for plants by means of their molecule constituents: application to meranzin. Planta Med. 73 (2007) 1235-1240
54. Koch M.A., et al. Charting biologically relevant chemical space: a structural classification of natural products (SCONP). Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 17272-17277
55. Nören-Müller A., et al. Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 10606-10611
56. Koch M.A., et al. Compound library development guided by protein structure similarity clustering and natural product structure. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 16721-21676
57. Scheck M., et al. Synthesis of dysidiolide-inspired compound library and discovery of acetylcholinesterase inhibitors based on protein structure similarity clustering. Tetrahedron 64 (2008) 4792-4802
58. Stockwell B.R. Exploring biology with small organic molecules. Nature 432 (2004) 846-854
59. Bol D., and Ebner R. Gene expression profiling in the discovery, optimization and development of novel drugs: one universal screening platform. Pharmacogenomics 7 (2006) 227-235
60. Sleno L., and Emili A. Proteomic methods for drug target discovery. Curr. Opin. Chem. Biol. 12 (2008) 46-54